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Background. Respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and influenza are respiratory pathogens
leading to hospitalization in adults. Our understanding of the disease burden is limited to data from single-center or 1-season studies
in elderly patients. The HARTI study allows comparison of risk factors for progression to severe disease and medical resources utilization (MRU) during and post-hospitalization in adults diagnosed with influenza, RSV, or hMPV.
Methods. This was a prospective global study in adults hospitalized with acute respiratory tract infection (40 centers, 12 countries). Participants with influenza, RSV, or hMPV were enrolled in a substudy and followed for up to 3 months postdischarge.
Results. Overall, 366 influenza, 238 RSV, and 100 hMPV-infected participants enrolled in the substudy. RSV participants were
older and had greater frequency of risk factors and longer duration of symptoms before hospitalization than influenza participants.
The RSV and hMPV groups received more bronchodilators, corticosteroids, and oxygen supplementation. No significant differences
in intensive care unit admissions or complications were observed. Readmission occurred in 20%–33% of patients within 3 months
postdischarge, with the highest rates for RSV and hMPV. In-hospital death occurred in 2.5% of RSV, 1.6% of influenza, and 2% of
hMPV participants. In multivariate analyses, length of stay was independently associated with country, renal disease, and increased
age; probability of receiving supplemental oxygen was associated with pathogen (hMPV > RSV > influenza), abnormal chest x-ray,
and increased age.
Conclusions. Although influenza is more frequent, the HARTI study demonstrates greater frequency of underlying risk factors
and MRU for RSV and hMPV vs influenza in hospitalized adults, indicating a need for effective interventions.
Keywords. global prospective study; Influenza; RSV; hMPV; medical resource utilization.
Lower respiratory tract infections (LRTIs) are a leading cause
of mortality and morbidity worldwide, resulting in almost
2.38 million deaths in 2016, making LRTI the sixth leading
cause of mortality for all ages [1]. In a systematic analysis of
the global burden of disease in adults in 2010, about 500 000
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deaths annually were linked to influenza and 250 000 to respiratory syncytial virus (RSV) infections [2]. In a prospective
study among hospitalized adults aged ≥50 years, mortality was
comparable between human metapneumovirus (hMPV) and
RSV-infected patients [3].
Influenza is a well-recognized respiratory pathogen, with annual
epidemics affecting 5%–20% of the global unvaccinated population
in all age groups, resulting in 3–5 million cases of severe illness and
250 000 to 500 000 deaths [2, 4, 5]. The rates of serious influenza
illness and death are highest among persons aged <2 years or ≥65
years and those who are immunocompromised or have medical
conditions such as asthma, chronic obstructive pulmonary disease
(COPD), cardiovascular disease, or diabetes [6–9].
There is increasing yet incomplete evidence of the burden
associated with RSV and hMPV infection in adults. A
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Risk Factors and Medical Resource Utilization of
Respiratory Syncytial Virus, Human Metapneumovirus,
and Influenza-Related Hospitalizations in Adults—A
Global Study During the 2017–2019 Epidemic Seasons
(Hospitalized Acute Respiratory Tract Infection [HARTI]
Study)

Nasal
sampling part
of SOCa

Enrollment visit
SOC nasal swab for detection and
identification of respiratory pathogens
using rapid PCR was analyzed locally
Midturbinate swab for confirmatory
detection and identification using
multiplex PCR, and viral load

resources utilization (MRU) during hospitalization and up to 3
months post–hospital discharge were compared between RSV,
hMPV, and influenza patients.
METHODS
Study Design

This was a prospective cohort study in adult patients (≥18
years old) hospitalized with ARTI during the influenza/RSV/
hMPV season at 40 centers across 12 countries (Australia,
Argentina, Brazil, Canada, France, Germany, Japan, Malaysia,
Mexico, Republic of Korea, South Africa, United States), over
2 consecutive epidemic seasons (2017–2019). The clinical diagnosis of ARTI and decision to hospitalize the patient were
made according to local standard-of-care (SOC) practices.
The enrollment period was guided based on the local epidemic
wave progression. The study included 2 parts: a main study and
a substudy (Figure 1). Participants were consented and enrolled
in the main study within 24 hours after admission. Viral testing
was done as part of SOC or by study-specific molecular diagnostic testing, if not performed as SOC. All tests (whether SOC
or study-specific) used reverse transcription polymerase chain
reaction–based technology. Participants with influenza (up to a
cap of the first 380 consecutive participants), RSV, or hMPV infection were invited to enroll in the substudy, which comprised
a hospitalization phase with 3 visits (enrollment, 48 hours after
enrollment, and within ~2 days before planned discharge) and a
follow-up phase with telephone interviews at 1, 2, and 3 months
postdischarge. This report describes results from the substudy
(refer to Supplementary Table 1 for the main study population).

Positive
influenza/RSV/
hMPV test
results

Hospitalization
for ARTI

Nasal
sampling not
part of SOC

Enrollment visit
Mid-turbinate nasal swab collected for
detection and identification of respiratory
pathogens using rapid PCR, confirmation
using multiplex PCR, and viral load

Main study
Clinician-reported questionnaires
(baseline)

Positive
influenza/RSV/
hMPV test
results

Hospitalization phase
(48 hours after enrollment,
up to 2 days before the
planned hospital discharge,
at dischargeb)

Home-Based Follow-up
Phase
Patient-reported
questionnaires via
telephone interviews at 1,
2, and 3 months postdischarge

Collection of:
Nasopharyngeal swab
for biome (optional)
Clinician and patientreported questionnaires

Substudy
Patient-reported questionnaires:
Clinician-reported questionnaires
(48 hours after enrollment, up to 2 IADL, ADL, RiiQ, RSB, EQ-5D-5L, MRU
(48 hours after enrollment, up to 2
days before the planned hospital
days before planned discharge,b and at 1, 2,
discharge, at dischargeb)
and 3months postdischarge)

Figure 1. Study design schema. aWhen nasal swab collected as part of SOC, midturbinate swab (collected from opposite nostril than used for SOC test). bIf a participant
was hospitalized for a short period (ie, <72 hours) or transferred to another ward, an early discharge assessment was performed on the day of discharge. Abbreviations:
ADL, activities of daily living; ARTI, acute respiratory tract infection; EQ-5D-5L, EuroQol 5 Dimensions 5 Levels; hMPV, human metapneumovirus; IADL, instrumental activities of daily living; MRU, medical resource utilization; PCR, polymerase chain reaction; RiiQ, Respiratory Intensity and Impact Questionnaire; RSB, Respiratory Symptoms
Bother and Change in Health Status Questionnaire; RSV, respiratory syncytial virus; SOC, standard of care.
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prospective study in the United States revealed that 3%–7% of
healthy elderly adults (≥65 years of age) and 4%–10% of highrisk adults (those with chronic heart or lung disease) suffer
from RSV infection annually, with an estimated 177 000 hospitalizations and 14 000 deaths attributable to RSV each year
in adults aged ≥65 years [6]. The burden of RSV infection
in older adults may be underestimated due to lack of routine testing, low awareness among providers, and lack of
detectability when it results in an exacerbation of an underlying chronic cardiac or pulmonary condition [10]. Similar to
influenza, the risk of mortality is markedly increased among
the elderly who are hospitalized with RSV [11]. First recognized in 2001, hMPV has been identified as an important
cause of acute respiratory tract infections (ARTIs), affecting
all age groups, with severe infections in children aged <5
years, the elderly, and patients with cardiac, pulmonary, or
immunocompromising disease [12–15]. A prospective study
during 4 consecutive winter seasons showed an annual incidence of hMPV infection of 2.2%–10.5% in outpatient adults,
with 51% of patients developing symptomatic respiratory
illness. During the same period, hMPV was associated with
8.5% of adult hospitalizations due to acute cardiopulmonary
illness [15]. Like influenza, RSV and hMPV infections in
adults are associated with acute exacerbation of asthma and
COPD [9, 16, 17].
Many studies to date involve only older adults and provide
data from single centers, most commonly in the United States
and Europe [18]. The HARTI study aimed to further characterize adults throughout the age spectrum who were hospitalized with RSV, hMPV, and influenza. Risk factors and medical

Data Collection

Statistical Analysis

Data collected from study questionnaires were summarized using descriptive statistics. The National Early Warning
Score (NEWS), a tool that improves detection of clinical deterioration in adult patients, was calculated using vital signs
[19, 20]. The NEWS score consists of 7 graded physiological
measurements (respiratory rate, oxygen saturation, oxygen
supplementation, temperature, blood pressure, heart rate, level
of consciousness). Concomitant medications reported by the
clinician during hospitalization were described by frequency
distribution. Core risk factors for progression to severe disease (ie, hospitalization) and long-term sequelae (ie, slow recovery of lung function and functional capacity) were defined
as age >65 years, chronic heart or renal disease, COPD, and
asthma. Hospital length of stay (LOS) was summarized using
Kaplan-Meier (KM) analysis and described categorically (by
≤3 days or >3 days of stay). Pairwise comparisons were performed between RSV and hMPV vs influenza participants,
and any differences among the 3 respiratory pathogens were
assessed. Multivariate regression analysis was applied on hospital LOS and probability of receiving supplemental oxygen
during hospitalization. A multivariate accelerated failure time
(AFT) model with log-logistic likelihood was applied to investigate which baseline covariates impact the observed LOS. The
AFT model provides an alternative to the Cox proportional
hazards (PH) model in the analysis of time to event data [21,
22]. Whereas the PH model assumes that the risk factors multiply the hazard of hospital discharge by some constant, the
AFT model assumes that the risk factors have a multiplicative
effect (acceleration factor [AF]) on the LOS. For example, a binary covariate (eg, risk group indicator) with an estimated AF
of 1.49 would imply that patients at risk have an LOS 1.49 times
longer than patients without risks and thus a 49% increase in
LOS. To compare the results of the AFT model, a PH model
was fit using the covariates included in the multivariate AFT
model. More information on the advantages, model structure,

and interpretation of the AFT model are provided in the
Supplementary Data. P values without corrections for multiple
comparison are reported in Supplementary Tables 2–5.
RESULTS
Disposition

Overall, 3861 participants were consented and enrolled in the
main study between March 2, 2017, and October 31, 2019. Of
these 3861 participants, 26.1% (n = 1006) had a positive test for
influenza (16.7%), RSV (6.4%), hMPV (2.8%), or co-infection
between any of the 3 viruses (0.2%). Among these 1006 main
study participants with infections, 709 (18.1%) subsequently enrolled in the substudy, including 366 (9.5%) influenza-positive,
238 (6.2%) RSV-positive, and 100 (2.6%) hMPV-positive participants (and 5 [0.1%] participants with co-infections not described in this manuscript) (Figure 2).
Demographics and Baseline Clinical Characteristics

Almost half of the substudy participants were from the United
States (49.9%) (Table 1). Overall, 44.3% of participants were
between the ages of 18 and ≤64 years. The mean (SD) age of
participants overall was 65.6 (16.2) years and was significantly
higher among RSV participants (67.3 [16.5] years) compared
with influenza (64.4 [16.1] years; P = .032). The majority of participants were female (57.0%), with a higher proportion among
RSV compared with influenza cases (61.8% vs 52.7%, respectively; P = .035). A greater proportion of RSV participants had
core risk factors compared with influenza (86.1% vs 75.4%, respectively; P = .002). Similar trends toward a higher percentage
of female gender and more core risk factors with hMPV compared with influenza were noted, although differences were not
statistically significant. Age (≥65 years) was the most common
risk factor (influenza: 51.9%; RSV: 60.9%; hMPV: 57.0%) among
all respiratory pathogen groups, followed by heart disease (influenza: 38.8%; RSV: 41.6%; hMPV: 33.0%) and COPD (influenza: 22.1%; RSV: 30.7%; hMPV: 32.0%).
Reason for hospital admission was reported as both ARTI
and other underlying medical conditions for 52.3% overall
(RSV: 55.5%; influenza: 52.2%; hMPV: 46.0%). Underlying
asthma or COPD was more common among RSV (35.5%) and
hMPV (36.7%) participants compared with influenza (23.9%)
participants. The mean (SD) length of symptoms before hospitalization was longer for RSV (5.6 [7.3] days) and hMPV (5.1
[5.4] days) participants compared with influenza (4.5 [4.0]
days) participants, with a statistically significant difference between RSV and influenza (P = .013). Similarly, late presentation
(symptoms >3 days before hospitalization) was more common
among RSV (55.9%) and hMPV (53.0%) participants compared
with influenza (49.5%) participants. The mean (SD) NEWS
scale at screening was 4.2 (2.7) overall (RSV: 4.6 [2.7]; hMPV:
4.1 [2.5]; influenza: 4.0 [2.7]).
HARTI Global Study • OFID • 3
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Clinical information and hospital MRU were collected through
clinician-reported questionnaires (at enrollment, 48 hours after
screening, and within 2 days before planned discharge) and
through the MRU questionnaire during monthly phone interviews postdischarge. If the participant was discharged within
3 days of the enrollment visit, 1 hospital assessment was performed postbaseline (on the day of discharge). Vital signs and
complications, including lower respiratory, cardiovascular, and
other complications (Supplementary Figure 1), were collected
during hospitalization. An MRU questionnaire that assessed
hospital readmissions, medical consultations (general practitioner, internal medicine, pulmonologist, respiratory physiotherapy, or other), professional home care, and medications was
administered at 1, 2, and 3 months postdischarge.

Patients screened
n = 3911

Enrolled in main study
n = 3861

Positive for RSV
n = 249

Positive for
hMPV
n = 107

Positive for
co-infections
n=6

Negative tests
n = 2855

Enrolled in substudy (n = 709)

Positive for RSV
n = 238

Positive for
hMPV
n = 100

Positive for
co-infections
n=5

Early dischargea

n = 43 (11.7%)

n = 27 (11.3%)

n = 11 (11.0%)

n=0

48 hours after
enrollment

n = 302 (82.5%)

n = 200 (84.0%)

n = 84 (84.0%)

n = 4 (80.0%)

Up to 2 days
before discharge

n = 136 (37.2%)

n = 114 (47.9%)

n = 49 (49.0%)

n = 3 (60.0%)

1 month postdischarge

n = 308 (84.2%)

n = 209 (87.8%)

n = 91 (91.0%)

n = 5 (5.0%)

2 months postdischarge

n = 302 (82.5%)

n = 195 (81.9%)

n = 85 (85.0%)

n = 5 (5.0%)

3 months postdischarge

n = 296 (80.9%)

n = 194 (81.5%)

n = 76 (76.0%)

n = 5 (5.0%)

Assessment time points

Positive for
influenza
n = 366

Figure 2. Flow diagram of participants at each study visit. Patients having a positive result for 2 or more respiratory pathogens between FLU, RSV, and hMPV are presented
in the co-infections. All the percentages were calculated based on the total number of patients included for each pathogen. Missing patients at each study visit are not included in the diagram above. aIf a participant was hospitalized for a short period (ie, <72 hours) or transferred to another ward, an early discharge assessment was performed
on the day of discharge. Abbreviations: hMPV, human metapneumovirus; FLU, influenza; RSV, respiratory syncytial virus.

Medical Resource Utilization

MRU During Hospitalization

Hospital LOS varied by several factors including infecting
virus, country, age, and core risk factors (Table 2). The median
(interquartile range) LOS based on KM estimates was longer
for RSV (6.0 [4–9] days) compared with influenza (5.0 [3–7]
days) and hMPV (5.0 [4–9] days) participants (P = .0043), and
a greater proportion of RSV (73.5%) and hMPV (75.0%) participants had an LOS >3 days compared with influenza (70.8%)
participants. Overall, LOS was shortest in Mexico, the United
States, and Australia (KM median, 3.0, 4.0, and 4.0 days, respectively) and longest in Japan and France (median, 10.0
and 8.0 days, respectively; P < .0001) (Supplementary Figure
2). Longer stays were reported for participants who received
4 • OFID • Falsey et al

oxygen supplementation during hospitalization and in the 75+
years age group (P < .0001). Significantly longer LOS was also
reported in participants with core risk factors (P = .0003) and
high NEWS scale at enrollment (P < .0001).
The most common concomitant medications reported
were antibiotics and bronchodilators among RSV (75.2% and
73.5%, respectively) and hMPV (74.0% each) participants, and
antivirals (86.3%) for influenza participants (Supplementary
Figure 3). A greater proportion of RSV and hMPV participants
received oxygen supplementation during hospitalization (68.9%
and 67.0%, respectively) compared with influenza (52.7%) participants (P < .001).
Several trends, not statistically significant, were identified. Compared with influenza (39.6%) participants, a greater
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Positive for
influenza
n = 644

Table 1. Demographic and Baseline Clinical Characteristics by Respiratory Pathogen
Influenza (n = 366)

RSV (n = 238)

hMPV (n = 100)

Totala (n = 709)

64.4 (16.05)

67.3 (16.52)

65.9 (15.65)

65.6 (16.19)

65.5

70.0

69.0

67.0

(18–99)

(18–98)

(24–93)

(18–99)

.032b

.437c

.098d

147 (61.8)

62 (62.0)

404 (57.0)

.035b

.124c

.051d

205 (86.1)

85 (85.0)

570 (80.4)

.002b

.058c

.002d

145 (60.9)

57 (57.0)

395 (55.7)

.036b

.429c

.089d

99 (41.6)

33 (33.0)

276 (38.9)

.548b

.345c

.334d

39 (16.4)

22 (22.0)

109 (15.4)

.231b

.027c

.055d

51 (21.4)

20 (20.0)

120 (16.9)

.007b

.099c

.014d

73 (30.7)

32 (32.0)

187 (26.4)

.024b

.056c

.026 d

28 (11.8)

11 (11.0)

96 (13.5)

.232b

.323c

.292d

Age, y
Mean (SD)
Median
(Range)
Female gender, No. (%)

193 (52.7)

P value
Presence of core risk factor, No. (%)e

276 (75.4)

  P value
Age ≥65 y

190 (51.9)

  P value
Chronic disease–heart disease

142 (38.8)

  P value
Chronic disease–renal disease

46 (12.6)

  P value
Asthma

47 (12.8)

  P value
Respiratory tract morbidity–COPD

81 (22.1)

  P value
Presence of other risk factor, No. (%)

f

57 (15.6)

  P value
COPD severity, No. (%)
No.

81

73

32

187

Mild

20 (24.7)

10 (13.7)

6 (18.8)

36 (19.3)

Moderate

18 (22.2)

20 (27.4)

7 (21.9)

46 (24.6)

7 (8.6)

17 (23.3)

6 (18.8)

30 (16.0)

36 (44.4)

26 (35.6)

13 (40.6)

75 (40.1)

.032b

.481c

.1776d

143 (60.1)

73 (73.0)

388 (54.7)

.001b

<.001c

<.001d

132 (36.2)

93 (39.1)

58 (58.0)

286 (40.4)

1 (0.3)

0

0

1 (0.1)

.508b

<.001c

<.001d
5.0 (5.50)

Severe
Not reported
P value
Previous vaccinations, No. (%)
Influenzag

169 (46.2)

  P value
Pneumococcal
  Missing
  P value
Symptom length before hospitalization, d
Mean (SD)

4.5 (4.01)

5.6 (7.27)

5.1 (5.35)

Median

3.0

4.0

4.0

4.0

Range

(0–31)

(0–92)

(0–35)

(0–92)

.013b

.420c

.045d

165 (45.1)

100 (42.0)

51 (51.0)

319 (45.0)

10 (2.7)

6 (2.5)

3 (3.0)

19 (2.7)

191 (52.2)

132 (55.5)

46 (46.0)

371 (52.3)

.733b

.548c

.636d

29 (12.5)

10 (10.3)

58 (8.4)

.003b

.124c

.007d

26 (11.2)

8 (8.2)

78 (11.3)

.849b

.380c

.571d

61 (26.3)

26 (26.8)

140 (20.3)

.001 b

.008c

.001d

65 (28.0)

22 (22.7)

237 (34.3)

.001 b

.001c

.001d

86 (37.1)

42 (43.3)

268 (38.8)

.744 b

.489c

.572d

6 (2.5)

3 (3.0)

19 (2.7)

P value
Reason for hospital admission
Only ARTI
Only underlying medical conditions other than ARTI
Both ARTI and underlying medical conditions other than ARTI
P value
Type of ARTI, No. (%)
Asthma exacerbation

19 (5.3)

  P value
Bronchitis

43 (12.1)

  P value
COPD exacerbation

52 (14.6)

  P value
Otherh

148 (41.6)

  P value
Pneumonia

138 (38.8)

  P value
Missing

10 (2.7)
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P value

Table 1.

Continued
Influenza (n = 366)

RSV (n = 238)

hMPV (n = 100)

Totala (n = 709)

Asthma or COPD

48 (23.9)

49 (35.5)

18 (36.7)

116 (29.7)

Congestive heart failure

24 (11.9)

21 (15.2)

5 (10.2)

50 (12.8)

Sepsis

26 (12.9)

13 (9.4)

4 (8.2)

43 (11.0)

Hypoxemia

53 (26.4)

39 (28.3)

12 (24.5)

105 (26.9)

Type of underlying medical condition other than ARTI, No. (%)

51 (24.9)

16 (11.6)

10 (20.4)

76 (19.5)

186 (50.8)

157 (66.0)

64 (64.0)

409 (57.7)

<.001b

.026c

<.001d
4.22 (2.682)

P value
NEWS score at screening
Mean (SD)

3.99 (2.723)

4.64 (2.677)

4.12 (2.461)

Median

4.00

5.00

4.00

4.00

Range

(0.0–13.0)

(0.0–12.0)

(0.0–11.0)

(0.0–13.0)

35 (9.6)

23 (9.7)

15 (15.0)

74 (10.4)

.012b

.589c

.039d

Missing
P value

Abbreviations: ANOVA, analysis of variance; ARTI, acute respiratory tract infection; COPD, chronic obstructive pulmonary disease; hMPV, human metapneumovirus; RSV, respiratory syncytial virus.
a

Participants with co-infections (between influenza and/or RSV and/or hMPV; n = 5) are not displayed in this table but are included in the Total column.

b

P value based on Student t test (age), Wilcoxon rank-sum test (symptom length, NEWS score), or chi-square test (categorical variables) for the pairwise comparison between RSV and
influenza participants.
c
P value based on Student t test (age), Wilcoxon rank-sum test (symptom length, NEWS score), or chi-square test (categorical variables) for the pairwise comparison between hMPV and
influenza participants.
d
P value based on 1-way ANOVA (age), Kruskal-Wallis rank-sum test (symptom length, NEWS score), or chi-square test (categorical variables) for differences between influenza, RSV and
hMPV participants.
e

Core risk factors: age ≥65 years, chronic heart disease, COPD, chronic renal disease, asthma.

f

Other risk factors: behavior risk factor–alcoholism, behavior risk factor–other, behavior risk factor–smoking (≥20 cigarettes/d), chronic disease–HIV infection, chronic disease–liver disease,
chronic disease–lung disease, chronic disease–other, congenital or acquired immunodeficiencies, diabetes, diagnosed atopy–hay fever, diagnosed atopy–other, neoplasia, neurological and/
or neuropsychiatric condition, neuromuscular disorder–multiple sclerosis, neuromuscular disorder–myasthenia gravis, neuromuscular disorder–other, other, pregnancy, respiratory tract morbidity–cystic fibrosis, respiratory tract morbidity–other, respiratory tract morbidity–pulmonary hypertension, upper airway abnormality–other, upper airway abnormality–subglottic stenosis.
g

“Previous influenza vaccination” refers to vaccine receipt in the prior season.

h

Other types of ARTI (free-text) primarily consisted of viral influenza-like ARTI.

proportion of RSV and hMPV participants had complications during hospitalization (42.4% and 45.0%, respectively).
Admission to the intensive care unit (ICU) and length of ICU
stay were higher among RSV participants (12.2%; mean [SD],
9.1 [13.4] days) compared with influenza participants (7.7%;
mean [SD], 8.0 [9.6] days). Twenty-three (3.2%) participants
required mechanical ventilation, and 14 (2.0%) participants
died during hospitalization (influenza: 1.6%; RSV: 2.5%; hMPV:
2.0%).
MRU Postdischarge

Overall, 24.4% of participants were readmitted to the hospital
within 3 months postdischarge for any reason, with more readmissions among the RSV (26.6%) and hMPV (33.0%) groups
compared with influenza (20.4%; P = .101 and P = .018 for RSV
and hMPV, respectively, vs influenza). The majority of participants had at least 1 medical consultation postdischarge; most
occurred in the RSV (81.0%) and hMPV (93.4%) groups compared with influenza (73.7%; P = .062 and P < .001 for RSV
and hMPV, respectively, vs influenza). Bronchodilators were
the main type of medication received postdischarge in over half
of the RSV (51.4%) and hMPV (51.6%) participants, compared
with 37.6% of influenza participants. A total of 103 (16.3%)
participants overall reported using oxygen supplementation
6 • OFID • Falsey et al

postdischarge, with a higher proportion observed among hMPV
(20.9%) and RSV (19.4%) participants, compared with influenza (12.9%) participants. Among 104 participants with COPD
who did not receive oxygen before hospitalization, 21.2% received oxygen supplementation postdischarge. Eleven participants died during follow-up (influenza: 1.4%; RSV: 2.1%;
hMPV: 1.0%).
Multivariate Assessments

A multivariate AFT model showed that participants with
chronic renal disease had a significant increase in LOS compared with those without renal impairment (AF, 1.22; 95%
CI, 1.08–1.39; P = .0013), as well as oxygen supplementation
at screening (AF, 1.37; 95% CI, 1.26–1.49; P < .0001). Hospital
LOS increased for 10-year increase in age (AF, 1.05; 95% CI,
1.01–1.08; P = .0054). Compared with influenza participants,
hMPV participants had a significant increase in LOS (AF, 1.18;
95% CI, 1.03–1.35; P = .0143), and RSV participants had a
nonsignificant increase in LOS (AF, 1.09; 95% CI, 0.99–1.20;
P = .0769) (Figure 3; Supplementary Table 3).
A multivariate logistic regression model showed that the
probability of receiving oxygen supplementation during hospitalization was significantly higher for RSV (OR, 1.57; 95%
CI, 1.02–2.45) and hMPV participants (OR, 1.93; 95% CI,
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Other
O2 supplement at screening visit

Table 2. Morbidity and Medical Resource Utilization During Hospitalization and Postdischarge

MRU during hospitalization, No.

Influenza

RSV

hMPV

Totala

366

238

100

709

Highest clinical setting, No. (%)
ICU

29 (12.2)

8 (8.0)

65 (9.2)

209 (87.8)

92 (92.0)

644 (90.8)

.085b

1.00c

.153d

9 (3.8)

5 (5.0)

23 (3.2)

.463b

.192c

.325d

179 (75.2)

74 (74.0)

499 (70.4)

.027b

.185c

.048d

133 (55.9)

62 (62.0)

424 (59.8)

.177b

1.00c

.317 d

175 (73.5)

74 (74.0)

432 (60.9)

<.001 b

<.001c

<.001d

150 (63.0)

60 (60.0)

375 (52.9)

<.001b

.005c

<.001d

34 (14.3)

7 (7.0)

362 (51.1)

<.001b

<.001c

<.001d

193 (52.7)

164 (68.9)

67 (67.0)

426 (60.1)

6 (1.6)

6 (2.5)

4 (4.0)

16 (2.3)

  Nasal

183 (50.0)

154 (64.7)

67 (67.0)

406 (57.3)

  Other

19 (5.2)

19 (8.0)

1 (1.0)

39 (5.5)

<.001b

.015c

<.001d

101 (42.4)

45 (45.0)

294 (41.5)

.546b

.392c

.572d

53 (52.5)

22 (48.9)

148 (50.3)

.760b

1.00c

.884d

32 (31.7)

11 (24.4)

79 (26.9)

.245b

1.00c

.391d

37 (36.6)

21 (46.7)

115 (39.1)

.855b

.431c

.509d

17 (7.1)

3 (3.0)

42 (5.9)

.701b

.350c

.340d

6 (2.5)

2 (2.0)

14 (2.0)

  P value
Mechanical ventilation, No. (%)

9 (2.5)

  P value
Concomitant medications
Antibiotics

243 (66.4)

  P value
Antipyretics or antalgics

226 (61.7)

  P value
Bronchodilators

179 (48.9)

  P value
Corticosteroids

160 (43.7)

  P value
Direct antivirals

316 (86.3)

  P value
Supplemental oxygen
  Mechanical

  P value (supplemental oxygen)
Complications during hospitalization, No. (%)

145 (39.6)

  P value
Lower respiratory complicationse,f

72 (49.7)

  P value
e,g

Cardiovascular complications

35 (24.1)

  P value
Bacterial superinfectione,h

56 (38.6)

  P value
Confusion, No. (%)

22 (6.0)

  P value
Deaths during hospitalization, No. (%)
MRU postdischarge, No.
Medical consultations, No. (%)i

6 (1.6)
319

216

91

631

235 (73.7)

175 (81.0)

85 (93.4)

499 (79.1)

.062b

<.001c

<.001d

71 (22.3)

53 (24.5)

26 (28.6)

150 (23.8)

.611b

.267c

.447d

58 (26.9)

30 (33.0)

154 (24.4)

.101b

.018c

.029d

25 (11.6)

11 (12.1)

55 (8.7)

.031b

.080c

.038d

5 (2.1)

1 (1.0)

11 (1.6)

  P value
Professional home care, No. (%)j
  P value
Hospital admission postdischarge, No. (%)

65 (20.4)

  P value
Institutional care postdischarge, No. (%)

19 (6.0)

  P value
Deaths during follow-up

5 (1.4)

Abbreviations: hMPV, human metapneumovirus; ICU, intensive care unit; MRU, medical resource utilization; RSV, respiratory syncytial virus.
a

Participants with co-infections (between influenza and/or RSV and/or hMPV; n = 5) are not displayed in this table but are included in the Total column.

b

P value based on chi-square test and Fisher exact test (mechanical ventilation) for the pairwise comparison between RSV and influenza participants.

c

P value based on chi-square test and Fisher exact test (mechanical ventilation) for the pairwise comparison between hMPV and influenza participants.

d

P value based on chi-square test and Fisher exact test (mechanical ventilation) for differences between influenza, RSV, and hMPV participants.

e

No. = participants who indicated “yes” for complications during hospitalization.

f

Lower respiratory complications included respiratory distress, arrest, and failure, empyema, other.

g

Cardiovascular complications included exacerbation of heart failure, atrial fibrillation, acute coronary events, acute cerebrovascular events.

h

Bacterial superinfection based on clinical judgment.

i

Medical consultations is set to “yes” if at least 1 of the following resources was used: general practitioner, internal medicine, pulmonologist, respiratory physiotherapy, or other.

j

Professional home care is set to “yes” if at least 1 of the following resources was used: general practitioner, nurse, respiratory physiotherapy, or other.
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28 (7.7)
338 (92.3)

Inpatient ward

P values
Pathogen: FLU
Pathogen: HMPV

.0143

Pathogen: RSV

.0769

Age: 10-year increase

.0054

<.0001

Country: ARG

.5851

Country: AUS

<.0001

Country: BRA

.3830

Country: CAN

.0002

Country: DEU

<.0001

Country: FRA

<.0001

Country: JPN

<.0001

Country: KOR
Country: MEX

.5896

Country: MYS

.0011

Country: ZAF

.0010

Chronic renal disease: No
.0013

Chronic renal disease: Yes
Risk factor: None
Risk factor: Core risk

.1109

Risk factor: Other risk

.1035

Additional underlying medical

conditiona:

No

Additional underlying medical conditiona: Yes

.0402

X-ray finding: Normal
X-ray finding: Abnormal

.0061

X-ray finding: Not done/available

.2842

Oxygen supplementation at screening: No
Oxygen supplementation at screening: Yes

<.0001
0

0.5

1

1.5

2

2.5

3

Acceleration factor
Figure 3. Multivariate accelerated failure time model results for the length of hospital stay. Acceleration factors and 95% CIs of the variable included in the final model
are presented. Rows without estimates are the reference category for that variable. aAdditional underlying medical condition on top of ARTI. Abbreviations: AF, acceleration factor; ARG, Argentina; ARTI, acute respiratory tract infection; AUS, Australia; BRA, Brazil; CAN, Canada; DEU, Germany; FRA, France; FLU, influenza; hMPV, human
metapneumovirus; JPN, Japan; KOR, Korea; MEX, Mexico; MYS, Malaysia; RSV, respiratory syncytial virus; USA, United States of America; ZAF, South Africa.

1.06–3.59) compared with influenza participants (P = .0424 and
P = .0347, respectively). The probability was significantly lower
compared with the United States in the following countries:
Brazil (OR, 0.19; 95% CI, 0.07–0.47; P = .0003), Korea (OR, 0.21;
95% CI, 0.09–0.48; P = .0002) and Malaysia (OR, 0.31; 95% CI,
0.12–0.77; P = .0123). The probability of receiving oxygen supplementation was significantly higher for every 10-year increase
8 • OFID • Falsey et al

in age (OR, 1.28; 95% CI, 1.13–1.46; P = .0001), for participants
with COPD compared with no COPD (OR, 2.54; 95% CI, 1.51–
4.37; P = .0006), and for participants with abnormal x-ray findings compared with normal x-ray findings (OR, 2.05; 95% CI,
1.34–3.14; P = .0010) (Figure 4; Supplementary Table 5).
The results of the Cox proportional hazards model are presented in the Supplementary Data. Overall, conclusions were
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Country: USA

P values
Pathogen: FLU
Pathogen: HMPV

.0347

Pathogen: RSV

.0424

Country: USA
.1269

Country: AUS

.0522

Country: BRA

.0003

Country: CAN

.0555

Country: DEU

.1323

Country: FRA

.1232

Country: JPN

.1208

Country: KOR

.0002

Country: MEX

.1588

Country: MYS

.0123

Country: ZAF

.7105

Age:10-year increase

.0001

Sex: Male
Sex: Female

.0085

COPD: NO
.0006

COPD: Yes
Diabetes: NO
Diabetes: Yes

.0919

X-ray finding: Normal
X-ray finding: Abnormal

.0010

X-ray finding: Not done/available

.7813

ARTI: Bronchitis/Pneumonia/COPD exac/Asthma exac
.0007

ARTI: Other
Additional underlying medical condition*: No
Additional underlying medical condition*: Yes

<.0001

News scale: Low
News scale: Moderate

.0001

News scale: High

<.0001

News scale: Missing

.4368
0.05

0.25 0.5

1

2 3

5

10

20

40

Odds ratio [95% CI]
Figure 4. Multivariate logistic regression model results for the probability of receiving supplemental oxygen during hospitalization. Odds ratios and 95% CIs of the variable included in final model are presented. Rows without estimates are the reference category for that variable. aAdditional underlying medical condition on top of ARTI.
Abbreviations: ARG, Argentina; ARTI, acute respiratory tract infection; AUS, Australia; BRA, Brazil; CAN, Canada; DEU, Germany; FRA, France; FLU, influenza; hMPV, human
metapneumovirus; JPN, Japan; KOR, Korea; MEX, Mexico; MYS, Malaysia; NEWS, National Early Warning Score; RSV, respiratory syncytial virus; USA, United States of
America; ZAF, South Africa.

similar between the Cox proportional hazards model and the
multivariate AFT model.
DISCUSSION

HARTI provides global prospective data on risk factors and
MRU associated with RSV, hMPV, and influenza during hospitalization and after hospital discharge in adults. This study

sheds light on the burden of these respiratory pathogens, regardless of age, as 44.3% patients were <65 years of age. RSV,
hMPV, and influenza were diagnosed in 26% of ARTI hospitalizations screened. While influenza remains the most recognized viral respiratory pathogen diagnosed in adults, the results
of the HARTI study confirmed the significant MRU associated
with RSV and expanded the existing literature regarding MRU
associated with hMPV infection. Although many similarities
HARTI Global Study • OFID • 9
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health care sooner. The prolonged time to presentation is a significant challenge for testing and implementing early antiviral
treatments for influenza, RSV, and hMPV.
Increased age, presence of chronic renal disease, and oxygen
supplementation at screening were associated with increased
LOS in the multivariate regression model. Similar to other publications [29], country/region influence on LOS was found;
LOS was shortest in the United States, Australia, Canada, and
Mexico and was longer in all other participating countries, with
the longest LOS for Japan and Korea.
After adjusting for possible confounders, the probability of
receiving oxygen supplementation during hospitalization was
significantly higher for RSV and hMPV compared with influenza and for those with increased age, presence of COPD, and
abnormal chest x-ray findings. Country-specific influence on
probability of receiving oxygen was observed, with lower probability for Brazil, Korea, and Malaysia, compared with the United
States. This trend could be related to the limited availability of
medical oxygen in developing countries and different prescription practices. Medical oxygen is more readily available and less
expensive in the United States and Europe, as has been highlighted by the recent COVID-19 pandemic [30, 31]. The burden
of disease in many countries is still largely unexplored and deserves further study.
Strengths and Limitations

This was a prospective global study with a large number of participants, allowing for the assessment of disease severity and MRU
during hospitalization and up to 3 months postdischarge. The
study included 44.3% adults aged 18–≤64 years, whereas many
previous studies have been conducted in elderly populations.
HARTI was a prospective study conducted in 12 countries in both
hemispheres over 2 full consecutive epidemic seasons, while other
studies, particularly those assessing hMPV, have been limited to 1
country and are often retrospective. Some limitations should be
noted: Despite the global design of HARTI, a large proportion of
participants were enrolled from the United States (49.9%), limiting
conclusions from countries with smaller sample sizes. However,
the baseline characteristics of participants enrolled from other
countries were similar to those of the United States. Most (88.4%)
participants were enrolled on weekdays by protocol and may have
differed from participants admitted to the hospital on weekends
or holidays. The decision to discharge and provide oxygen supplementation followed the site’s SOC, whereas in the multivariate
analysis, the data were pooled at the country level. Additionally,
no source data verification cross-check of the clinician-reported
questionnaires with the patient’s medical file was performed.
CONCLUSIONS

RSV and hMPV participants had a greater frequency of underlying risk factors, including age >65 years, and substantial MRU during hospitalization and postdischarge compared
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exist for the populations affected and clinical syndromes resulting from infection with influenza and other respiratory viruses, there is now growing evidence that suggests that subtle
differences exist that may help target at-risk populations for
interventions and support a better understanding of disease
pathogenesis. In this study of hospitalized adults, RSV patients
were older and had a greater frequency of underlying risk factors, as well as higher NEWS scale at screening, compared with
influenza patients. Similar trends were noted for hMPV, though
they did not reach statistical significance. Whether due to age
or underlying conditions, the outcomes for RSV tended to be
worse, with higher needs for supplemental oxygen, in-hospital
complications, longer LOS, higher ICU use, and longer length
of ICU stay. RSV and hMPV patients also showed greater
MRU postdischarge, including hospital readmissions and medical consultations, than influenza patients. Long-term disease
sequelae and postdischarge MRU were considerable, including
all-cause 3-month readmission (24% overall) and new start of
home-based therapy in 21% of COPD patients.
Other authors have noted similar findings when comparing
RSV and influenza hospitalizations [10, 23, 24]. Tseng et al.
(2020) reported high levels of MRU for RSV patients during
hospitalization, with 21.4% of patients requiring ventilation support and 17.9% admitted to the ICU, as well as hospital readmissions within the first 30 days postdischarge exceeding 15% and
substantial health care services utilization postdischarge [25].
Akerson et al. (2019) found that RSV infection was associated
with greater odds of LOS ≥7 days and ICU admission in adjusted
analyses compared with adults hospitalized with influenza [26].
Falsey et al. (1995) showed that RSV patients were more likely to
receive therapy for bronchospasm and had a higher death rate
than influenza patients [27]. In Bruyndonckx et al. (2020), the
odds of having unresolved symptoms after 28 days and illness
deterioration were significantly associated with age in RSV patients but not in influenza patients [16]. Furthermore, Sieling et
al. (2021) found that RSV and hMPV were both associated with
a longer median LOS (4.4 and 4.8 days, respectively) compared
with influenza (3.9 days), with higher crude mortality [24]. In
the current study, hMPV infections presented similar trends toward higher MRU compared with influenza. Although data are
limited, other reports describe similar findings. In a recent study
from France, hMPV patients were more frequently aged >65
years and presented with more acute heart failure during hospitalization compared with influenza patients [28].
In the current study, both RSV and hMPV participants had a
longer duration of symptoms before hospitalization than participants with influenza. Others have made similar observations,
and in a previous study [3], the median length of symptoms
before hospital admission was the longest for RSV (6.5 days)
in comparison to influenza and hMPV (both 5.0 days). The
differences in time to presentation may reflect higher rates of
systemic symptoms for influenza patients, leading them to seek
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with influenza participants. RSV participants had the longest
length of symptoms before hospitalization, longest median
LOS, highest proportion of ICU admission, and a significantly
higher probability of receiving oxygen supplementation during
hospitalization. Significant differences in LOS were observed by
country. The results of the HARTI study expand upon existing
literature and highlight the significant MRU associated with
RSV and hMPV in hospitalized adults, indicating a need for effective interventions and informing future vaccine and antiviral
research agendas.

